Biqi Chen
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 10, 2026
Adding anti-PD-1 antibody to definitive chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: higher intensity does not equate to better outcomes.
Journal: Annals of medicine
Published: February 02, 2026
Serum cytokines predict response and survival in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with anti-PD-1 antibody: analyses of two phase II clinical trials.
Journal: Journal for immunotherapy of cancer
Published: December 30, 2025
Concurrent Chemoradiotherapy with or without Induction Chemoimmunotherapy in Unresectable Esophageal Squamous Cell Carcinoma: A Multicenter Real-World Study.
Journal: Cancer research and treatment
Published: November 07, 2025
In Reply to Noguchi et al.
Journal: International journal of radiation oncology, biology, physics
Published: July 29, 2024
Comparison of Efficacy and Safety of Combined Chemoimmunotherapy With or Without Radiation Therapy for Stage IVB Esophageal Squamous Cell Carcinoma: A Multicenter Propensity Score Matching Analysis.
Journal: International journal of radiation oncology, biology, physics
Published: March 22, 2024
Management of metastatic bone disease of melanoma.
Journal: Melanoma research
Published: November 08, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026